Bromelain, a proteolytic enzyme complex extracted from pineapple, has been recognized for its therapeutic potential, particularly in the treatment of respiratory diseases.

The enzyme’s high enzymatic activity (GDU) is key to its efficacy in managing conditions such as acute respiratory infections, allergic rhinitis, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and post-COVID-19 syndrome (Long COVID).

Bromelain works through several mechanisms: mucolysis, inflammation suppression, immune modulation, and tissue repair.

When used in combination with complementary nutrients like quercetin, vitamin C, vitamin D, zinc, and elastin peptides, bromelain enhances the therapeutic outcomes by addressing multiple disease targets.

This multi-target approach is pivotal for improving symptom resolution, reducing inflammation, and facilitating recovery, making bromelain a promising adjunct in both acute and chronic respiratory disease management.